Antonios Katsounas1, Astrid C Frank2, Richard A Lempicki3, Michael A Polis2, David M Asmuth4, Shyam Kottilil2. 1. Department of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany ; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr., Bethesda, MD 20892, USA. 2. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Dr., Bethesda, MD 20892, USA. 3. Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 4. Division of Infectious and Immunologic Diseases, UC Davis, Medical Center 4150 V Street, PSSB G500 Sacramento, CA 95817, USA.
Abstract
OBJECTIVE: This study was aimed to correlate in vivo interferon (IFN) inducible gene (IFIG) expression and IFIG induction with viral-load (VL) and VL-kinetics of Human-Immunodeficiency-Virus (HIV) or Hepatitis-C-Virus (HCV) in HIV-positive patients treated with pegylated IFN-alpha-2a (PegIFNα). METHODS: HIV mono-infected patients (N=8) and HIV/HCV co-infected patients (N=23, without HIV-viremia) were treated with PegIFNα (180 μg/week) for 12 and 48 weeks, respectively. Blood sampling for monitoring IFIG expression occurred at day_0 and week_3, _6 and _12 for HIV mono-infected patients vs. only at day_0 and week_48 for HIV/HCV co-infected subjects. IFIG expression (N=20) was measured in peripheral blood mononuclear cells by bDNA-assay. VL levels/changes in plasma were analyzed for correlation with IFIG expression/induction at/between selected time points. Overall, P<0.05 was considered significant. RESULTS: None of the 20 IFIG expression profiles at day_0 correlated significantly with HIV-VL at day_0. Expression at day_0 of 3 IFIG (APOBEC3G/OAS1/OAS2) correlated significantly (r>+0.42/P<0.05) with HCV-VL at day_0. The strongest antiviral effect [measured as median viral decline per week: ΔVL/week (log10)] occurred in common against HIV and HCV between day_0 and week_3 during 12 weeks of continuous PegIFNα treatment in both cohorts. Expression at day_0 of 1 IFIG (APOBEC3A) correlated significantly (r<-0.71/P<0.05) with HIV-ΔVL/week (log10) from day_0 to week_3. No significance was reached in correlations between expression values of 20 IFIG at day_0 and HCV-ΔVL/week (log10) from day_0 to week_3. No significant correlation was detected between IFIG expression changes (ΔIFIG=induction) from day_0 to week_3 and HIV-ΔVL/week (log10) from day_0 to week_3. Interestingly, induction of 1 IFIG (ΔISG20) from day_0 to week_48 was significantly associated (P<0.05) with permanent HCV clearance. CONCLUSION: This study demonstrates the differential specificity of PegIFNα mediated molecular actions by dissecting the kinetics of IFIG expression and induction, suggesting multiple, possibly non-overlapping mechanisms for antiviral effects against HCV and HIV.
OBJECTIVE: This study was aimed to correlate in vivo interferon (IFN) inducible gene (IFIG) expression and IFIG induction with viral-load (VL) and VL-kinetics of Human-Immunodeficiency-Virus (HIV) or Hepatitis-C-Virus (HCV) in HIV-positivepatients treated with pegylated IFN-alpha-2a (PegIFNα). METHODS:HIV mono-infectedpatients (N=8) and HIV/HCV co-infectedpatients (N=23, without HIV-viremia) were treated with PegIFNα (180 μg/week) for 12 and 48 weeks, respectively. Blood sampling for monitoring IFIG expression occurred at day_0 and week_3, _6 and _12 for HIV mono-infectedpatients vs. only at day_0 and week_48 for HIV/HCV co-infected subjects. IFIG expression (N=20) was measured in peripheral blood mononuclear cells by bDNA-assay. VL levels/changes in plasma were analyzed for correlation with IFIG expression/induction at/between selected time points. Overall, P<0.05 was considered significant. RESULTS: None of the 20 IFIG expression profiles at day_0 correlated significantly with HIV-VL at day_0. Expression at day_0 of 3 IFIG (APOBEC3G/OAS1/OAS2) correlated significantly (r>+0.42/P<0.05) with HCV-VL at day_0. The strongest antiviral effect [measured as median viral decline per week: ΔVL/week (log10)] occurred in common against HIV and HCV between day_0 and week_3 during 12 weeks of continuous PegIFNα treatment in both cohorts. Expression at day_0 of 1 IFIG (APOBEC3A) correlated significantly (r<-0.71/P<0.05) with HIV-ΔVL/week (log10) from day_0 to week_3. No significance was reached in correlations between expression values of 20 IFIG at day_0 and HCV-ΔVL/week (log10) from day_0 to week_3. No significant correlation was detected between IFIG expression changes (ΔIFIG=induction) from day_0 to week_3 and HIV-ΔVL/week (log10) from day_0 to week_3. Interestingly, induction of 1 IFIG (ΔISG20) from day_0 to week_48 was significantly associated (P<0.05) with permanent HCV clearance. CONCLUSION: This study demonstrates the differential specificity of PegIFNα mediated molecular actions by dissecting the kinetics of IFIG expression and induction, suggesting multiple, possibly non-overlapping mechanisms for antiviral effects against HCV and HIV.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: I Wayne Cheney; Vicky C H Lai; Weidong Zhong; Tessa Brodhag; Shannon Dempsey; Charmaine Lim; Zhi Hong; Johnson Y N Lau; Robert C Tam Journal: J Virol Date: 2002-11 Impact factor: 5.103
Authors: Mohamed Abdel-Mohsen; Rui André Saraiva Raposo; Xutao Deng; Manqing Li; Teri Liegler; Elizabeth Sinclair; Mohamed S Salama; Hussam El-Din A Ghanem; Rebecca Hoh; Joseph K Wong; Michael David; Douglas F Nixon; Steven G Deeks; Satish K Pillai Journal: Retrovirology Date: 2013-10-16 Impact factor: 4.602
Authors: Daniela A Covino; Cristina Purificato; Laura Catapano; Clementina M Galluzzo; Maria Cristina Gauzzi; Stefano Vella; Eric Lefebvre; Star Seyedkazemi; Mauro Andreotti; Laura Fantuzzi Journal: Front Immunol Date: 2018-08-08 Impact factor: 7.561
Authors: Ramy El-Diwany; Mary Soliman; Sho Sugawara; Florian Breitwieser; Alyza Skaist; Candelaria Coggiano; Neel Sangal; Michael Chattergoon; Justin R Bailey; Robert F Siliciano; Joel N Blankson; Stuart C Ray; Sarah J Wheelan; David L Thomas; Ashwin Balagopal Journal: Sci Adv Date: 2018-08-01 Impact factor: 14.136